Vertex Pharmaceuticals and Zai Lab Limited announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept in mainland China, Hong Kong SAR, Macau SAR, Taiwan region, and Singapore. Povetacicept is a recombinant fusion protein therapeutic and dual antagonist of BAFF and APRIL, being studied for IgA Nephropathy (IgAN) and other B cell-mediated diseases.
Under the terms of the agreement, Vertex will receive an upfront payment, along with certain regulatory milestone payments and tiered royalties on net sales of povetacicept in the licensed territory. Zai Lab will utilize its research and development expertise to advance clinical trials and make regulatory submissions in the region.
Zai Lab will also be responsible for all commercialization activities in the licensed territory once povetacicept receives approval. This partnership aims to accelerate the development and market access of this potential best-in-class therapy for patients in a significant Asian market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.